Cargando…
A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascu...
Autores principales: | Zafar, Aneeqa Ahsan, Kouides, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141713/ https://www.ncbi.nlm.nih.gov/pubmed/32274030 http://dx.doi.org/10.1002/ccr3.2728 |
Ejemplares similares
-
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2022) -
Cardiac magnetic resonance imaging unmasks presumed embolic myocardial infarction due to patent foramen ovale case report
por: Liang, Kate, et al.
Publicado: (2022) -
Paclitaxel Induced MDS and AML: A Case Report and Literature Review
por: Bhatnagar, Udit Bhaskar, et al.
Publicado: (2016) -
Presumed isotretinoin-induced extraocular myopathy
por: Alam, Md. Shahid, et al.
Publicado: (2016) -
Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)